2/ Given the amount of discussion in scientific, public, and political spheres, it is useful to undertake a thought experiment examining crossreactive T cell effects on COVID-19 disease severity and herd immunity, should crossreactive memory T cells confer some form of protection
3/ We consider immunological and epidemiological aspects and implications of pre-existing crossreactive immune memory to SARS-CoV-2, largely originating from previous exposure to circulating common cold coronaviruses.
4/ We propose four immunological scenarios for the impact of crossreactive CD4+ memory T cells on COVID-19 severity and viral transmission. For each scenario, we discuss implications for herd immunity and projections of the global impact of SARS2.
5/ In sum, we argue potential impacts of crossreactive T cell memory are already ‘baked in’ to epidemiological models, particularly regarding herd immunity.
6/ The implications of immunological processes on other aspects of SARS2 epidemiology are worthy of future study, and discussed in the paper.
7/ We emphasize that any functional role for crossreactive T cell memory in COVID-19 remains unproven, but the thought experiment is helpful.
2) There is no direct evidence that pre-existing T cell immunity affects COVID-19 infections. LJI researchers and other have proven that such T cells exist, but neither we nor anyone else have shown that the pre-existing T cells make COVID-19 better, worse, or no difference.
3) To say it another way, There is no direct evidence that crossreactive memory T cells to common cold viruses affects COVID-19.
Crotty lab member of the week is Carolyn Rydyznski Moderbacher, PhD! 1. Carolyn is the lead author of our new COVID-19 immunology paper studying T cell and antibody responses in acute COVID-19 cases. cell.com/cell/fulltext/… @ljiresearch
2. Carolyn wasn’t planning on working on COVID-19, but she had developed excellent multi parameter flow cytometry panels for other human T cell studies, and AIM assays, and I needed her to take the lead on COVID-19 T cell work,
3. so she dropped her other project and has worked full time on COVID-19 for the past 6 months, trying to understand immunity to COVID-19. Culminating in the new paper.
2/ We aimed to better understand hospitalized COVID-19 cases by examining virus-specific immune responses all in the same people. SARS2-specific Helper T cells, killer T cells, and neutralizing antibodies.
3/ (I.e., measure the adaptive immune response in acute COVID-19 cases with virus-specific tools.)
Our newest COVID-19 immunology work is online today at Cell! bit.ly/3mugShW
We aimed to better understand hospitalized COVID-19 cases by examining virus-specific immune responses all in the same people. SARS2-specific Helper T cells, killer T cells, and neutralizing antibodies.
(I.e., measure the adaptive immune response in acute COVID-19 cases with virus-specific tools.)
1/ Crotty Lab member of the week: Yu (Alex) Kato
Alex led the work just published in @ImmunityCP on the multifaceted ways antigen valency affects B cell responses in vivo. That study is important for vaccine immunology, connecting vaccine designs to immunological rules.
2/ He used two photo intravital microscopy, custom engineered proteins, a variety of in vivo models manipulating antigen-specific B cells and CD4 T cells, and all kinds of flow cytometry to figure out this interesting and important puzzle. All told, it was almost 4 years of work!
3/ Alex has also been deeply involved in fantastically successful collaborations with Darrell Irvine's lab at MIT, including a novel vaccine delivery / adjuvant study in @NatureMedicine this year.
1/ Our new paper is out: Multifaceted Effects of Antigen Valency on B Cell Responses In Vivo. bit.ly/34MMKrJ
There is lots of excitement about nanoparticle vaccine designs, and a general consensus that multivalency is a good thing for vaccines. @ljiresearch@ImmunityCP
2/ But, mechanistic immunological understand of the impact of valency has been limited, for a variety of reasons. Here, we completed a four years study of valency and and affinity on antigen-specific B cell responses in vivo.
3/ We found that antigen valency dictates the magnitude and composition of B cell responses. Antigen valency alters breadth of B cell affinities recruited. And valency appears to modulate both the magnitude and the clonal compositions of GC responses.